Home
Storia in 4 fonti
Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop
Biogen and Denali Therapeutics’ LRRK2 inhibitor has flunked a Phase 2b trial in early Parkinson’s disease, leading the companies to drop the program in certain patients.
- ·
markets.businessinsider.com
Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints
Biogen (BIIB) and Denali Therapeutics (DNLI) announced topline results from the Phase 2b LUMA study evaluating BIIB122, an investigational small...
- ·
statnews.com
Closely watched experimental Parkinson’s drug fails key clinical trial
Biogen and Denali Therapeutics said a closely watched experimental therapy for Parkinson’s disease failed to slow the degenerative brain disorder in a randomized trial.
